Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsDiscoverX Corporation
Learn about diseases caused by protein misfolding and how you can screen for compounds, known as pharmacochaperones, that rescue misfolded proteins and could be used as therapeutics.
3D cultures of Patient derived Gliomas and Breast cancer - Optimized for drug...Rachna Goyal
Three-dimensional (3D) tumor cell culture models have been shown to represent a biologically relevant assay system. We've optimized methods to culture Patient derived Primary tumor cells in 2D & 3D formats. Over 20 + Gliomas and 40+ Breast cancer samples from unique patients have been cultured. These cultures are also enriched in Cancer stem cells !
Pls contact for more details:
Rachna@saarum.com
+91 7032647554
NGS for Infectious Disease Diagnostics: An Opportunity for Growth Alira Health
Infectious diseases are a major public health concern causing over 3.5 million deaths worldwide. Diagnosing patients as quickly and effectively as possible is crucial for managing disease outbreaks. Next-generation sequencing (NGS) provides unique capabilities to understand the genetic profile of infectious disease patients that no other technology can match.
Whole-genome metagenomics allows clinicians to take a deeper dive into pathogens by generating big-data about their characteristics. This data can be rapidly analyzed using complex bioinformatics software algorithms to achieve clinical-grade diagnostic accuracy. In a healthcare system shifting towards personalized medicine, NGS can provide clinicians the tools that they need to prescribe individualized treatments to save patients who were previously untreatable. The result is improved quality of care, better treatment regimes, and cost-saving healthcare.
A next generation sequencing based sample-to-result pharmacogenomics research...Thermo Fisher Scientific
Pharmacogenomics (PGx) is the study of genetic variations in terms of their response to drugs. Variations in gene sequence or copy numbers may result in complete loss of function, partial decrease or increase in enzyme activity, or an altered affinity for substrates, which may in turn significantly impact drug efficacy. PGx studies are becoming increasingly important for precision medicine. We have developed a next generation sequencing (NGS) PGx research solution with increased flexibility on the assay targets and combined detection of SNP/INDEL genotyping and CNV using Ion AmpliSeq™ technology for low to medium throughput laboratories. With this highly multiplexed PGx research panel we can profile a set of 136 genetic markers in 40 known PGx related genes (Table 1) and determine CYP2D6 copy number variation (CNV, Figure 1) in a single reaction using Ion Torrent™ semiconductor sequencing.
Answer four fundamental questions on how to develop the most innovative cancer immunotherapy treatments, starting with screening for lead molecules and ending with evaluation of combination therapies.
Moving Towards a Validated High Throughput Sequencing Solution for Human Iden...Thermo Fisher Scientific
Presented by Jennifer D. Churchill, PhD during a special Lunch and Learn session during the American Academy of Forensic Sciences (AAFS) 67th annual conference, February 2015. / Conclusions
• Robust panels of identity and ancestry SNPs
• Robust STR panel
• Whole genome mtDNA sequencing
• Highly informative
• Sensitive
• Quantitative – scaling comparison
• Low density chip is not necessarily a bad chip
• Wide range of density can still yield high quality data
• Based on results continue development and validation
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsDiscoverX Corporation
Learn about diseases caused by protein misfolding and how you can screen for compounds, known as pharmacochaperones, that rescue misfolded proteins and could be used as therapeutics.
3D cultures of Patient derived Gliomas and Breast cancer - Optimized for drug...Rachna Goyal
Three-dimensional (3D) tumor cell culture models have been shown to represent a biologically relevant assay system. We've optimized methods to culture Patient derived Primary tumor cells in 2D & 3D formats. Over 20 + Gliomas and 40+ Breast cancer samples from unique patients have been cultured. These cultures are also enriched in Cancer stem cells !
Pls contact for more details:
Rachna@saarum.com
+91 7032647554
NGS for Infectious Disease Diagnostics: An Opportunity for Growth Alira Health
Infectious diseases are a major public health concern causing over 3.5 million deaths worldwide. Diagnosing patients as quickly and effectively as possible is crucial for managing disease outbreaks. Next-generation sequencing (NGS) provides unique capabilities to understand the genetic profile of infectious disease patients that no other technology can match.
Whole-genome metagenomics allows clinicians to take a deeper dive into pathogens by generating big-data about their characteristics. This data can be rapidly analyzed using complex bioinformatics software algorithms to achieve clinical-grade diagnostic accuracy. In a healthcare system shifting towards personalized medicine, NGS can provide clinicians the tools that they need to prescribe individualized treatments to save patients who were previously untreatable. The result is improved quality of care, better treatment regimes, and cost-saving healthcare.
A next generation sequencing based sample-to-result pharmacogenomics research...Thermo Fisher Scientific
Pharmacogenomics (PGx) is the study of genetic variations in terms of their response to drugs. Variations in gene sequence or copy numbers may result in complete loss of function, partial decrease or increase in enzyme activity, or an altered affinity for substrates, which may in turn significantly impact drug efficacy. PGx studies are becoming increasingly important for precision medicine. We have developed a next generation sequencing (NGS) PGx research solution with increased flexibility on the assay targets and combined detection of SNP/INDEL genotyping and CNV using Ion AmpliSeq™ technology for low to medium throughput laboratories. With this highly multiplexed PGx research panel we can profile a set of 136 genetic markers in 40 known PGx related genes (Table 1) and determine CYP2D6 copy number variation (CNV, Figure 1) in a single reaction using Ion Torrent™ semiconductor sequencing.
Answer four fundamental questions on how to develop the most innovative cancer immunotherapy treatments, starting with screening for lead molecules and ending with evaluation of combination therapies.
Moving Towards a Validated High Throughput Sequencing Solution for Human Iden...Thermo Fisher Scientific
Presented by Jennifer D. Churchill, PhD during a special Lunch and Learn session during the American Academy of Forensic Sciences (AAFS) 67th annual conference, February 2015. / Conclusions
• Robust panels of identity and ancestry SNPs
• Robust STR panel
• Whole genome mtDNA sequencing
• Highly informative
• Sensitive
• Quantitative – scaling comparison
• Low density chip is not necessarily a bad chip
• Wide range of density can still yield high quality data
• Based on results continue development and validation
New Technology and Workflow for Integrated Collection, Stabilization and Puri...QIAGEN
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene® Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphony® PAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this webinar, this new technology development is presented in comparison to other existing technologies.
Visualizing Human Stem Cell Dynamics by Multicolor, Multiday High-Content Mic...InsideScientific
Visualizing the complex spatiotemporal dynamics of human stem cells as they proliferate and make cell fate decisions is key to improve our understanding of how to robustly engineer differentiated tissues for therapeutic applications.
In this webinar, Dr. Rafael Carazo Salas describes multicolor, multiday high-content microscopy pipelines that his group has recently developed to visualize the dynamical cell fate changes of human Pluripotent Stem Cells (hPSCs). In particular, he reviews the integrated experimental and computational approaches that his group has established, including novel “live” reporters of cell fate and multi-reporter hPSC lines generated by CRISPR/Cas9 allowing multiplexed monitoring of cell proliferation and fate dynamics, and exemplify the biological discoveries they are enabling.
Key Topics Include:
- Visualizing how human Pluripotent Stem Cells (hPSCs) proliferate and undergo early differentiation in vitro, by high content microscopy
- Learning about experimental and computational pipelines that enable cell fate monitoring at the collective and single-cell level
- Learning about novel “live” reporters of hPSC cell fate
A novel method for building custom ampli seq panels using optimized pcr primers Thermo Fisher Scientific
AmpliSeq™ is a next generation sequencing library preparation method for targeted re-sequencing that utilizes highly multiplexed PCR to amplify regions of interest. A key to successful AmpliSeq libraries is the primer panel used for target amplification. Until now primers have been available as pre-assembled ready-to-use panels, or as custom made-to-order panels. We describe a new process for creating customized panels consisting of optimized and verified PCR primers. The primer sets are available as whole genes (i.e., all of the primers needed to create libraries that cover the entire coding regions of genes) and are selectable on the ampliseq.com website by either uploading gene lists or choosing genes from disease research areas.
We show NGS sequencing data from 10 disease research-oriented panels, including newborn screening research and inherited cancer research, assembled from individual pre-verified gene sets. Panel performance data include coverage uniformity, reproducibility, and sensitivity and positive predictive value of variant calling. To demonstrate flexibility of panel content and performance, the coverage uniformity of the 59 genes recommended by the American College of Medical Genetics and Genomics for reporting of incidental findings (ACMG59) was evaluated by themselves and with up to 135 additional genes and shown to be ≥ 97% in all contexts. We also demonstrate the robustness of this method using a variety of sample types (fresh, frozen, and dried blood, cheek swabs) with both manual and fully automated library preparation methods. For Research use only. Not for use in diagnostic procedures.
Conferència a càrrec d'Enriqueta Felip. Oncòloga de l'Hospital Vall d'Hebron de Barcelona. Líder en la investigació de càncer de pulmó al VHIO. Membre de la Junta Directiva de la Societat Espanyola d'Oncologia Mèdica i de l'European Society for Medical Oncology. En el marc de la Jornada "Els nous reptes de la Medicina de Precisió" organitzada el 12 de novembre per la Societat Catalana de Gestió Sanitària
Developing Custom Next-Generation Sequencing Panels using Pre-Optimized Assay...Thermo Fisher Scientific
Targeted next-generation sequencing panels enable interrogation of multiple genes across many samples to more deeply understand human genetic disease. However, finding all relevant genes, developing robust, high performing multiplex panels, and implementing scalable, reproducible and accurate analysis pipelines is challenging. We present a coordinated suite of tools to facilitate genetic disease research. First, we developed the Content Selection Engine which organizes human diseases hierarchically, and links all diseases to a set of associated genes; and the Gene Scoring Algorithm which ranks genes by clinical relevance. We developed optimized assays for the
most studied 1000 disease research genes, and we are in the process of developing optimized assays for a further 4000 genes.
An interactive web interface allows scientists to select any disease of interest, display all associated genes, select any genes, and add additional genes, for any number of diseases. Empirical coverage for each gene can be visualized in IGV. A custom Ampliseq gene panel can be built using the optimized assays from all the selected genes. Optimized gene panels can be developed narrowly targeted to specific diseases, or larger gene panels can be developed for broader phenotypes. Disease categories include early onset neonatal phenotypes such as metabolic disorders, Severe Combined Immunodeficiency (SCID), heme disorders; and late onset disorders such as cancer predisposition and cardiovascular disorders.
Sequencing and functional genomics Unit_Biomedical Research Center of Aragon_...Pilar Mozas
Documento que presenta la cartera de servicios y el equipamiento del Servicio Científico Técnico de Secuenciación y Genómica Funcional de la Universidad de Zaragoza y el Instituto Aragonés de Ciencias de la Salud.
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2QIAGEN
Advanced prostate cancer is highly heterogeneous but this inter-patient heterogeneity has until recently not been understood. We have through an international research effort dissected the molecular landscape of advanced castration resistant prostate, elucidating key molecular targets in this group of diseases. We have also shown that PARP inhibitors have antitumor activity against a significant proportion of these cancers, mainly in men whose cancers harbor DNA repair defects.
Validation of Identity and Ancestry
SNP Panels for the Ion PGM™
Christopher Phillips, Carla Santos, Maria de la Puente,
Manuel Fondevila, Ángel Carracedo, Maviky Lareu
Forensic Genetics Unit,
University of Santiago de Compostela
A high-throughput approach for multi-omic testing for prostate cancer researchThermo Fisher Scientific
The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).
mHealth Israel_Ryo Kosaka_AIST_National Institute of Advanced Industrial Scie...Levi Shapiro
Presentation by Ryo Kosaka, Senior Research Scientist, Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST). Includes an overview of priority strategies in Life Sciences and Biotech and description of the organization of the Life Sciences and Biotech department. Recent projects include a Portable System for High-Speed DNA Quantification, Application of a cell microarray chip for clinical diagnosis and single cell analysis, Safe and Secure Artificial Heart, New diagnosis for liver fibrosis utilizing glycans, AIST ventures from the department of Life Science & Biotech as well as International cooperation.
New Technology and Workflow for Integrated Collection, Stabilization and Puri...QIAGEN
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene® Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphony® PAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this webinar, this new technology development is presented in comparison to other existing technologies.
Visualizing Human Stem Cell Dynamics by Multicolor, Multiday High-Content Mic...InsideScientific
Visualizing the complex spatiotemporal dynamics of human stem cells as they proliferate and make cell fate decisions is key to improve our understanding of how to robustly engineer differentiated tissues for therapeutic applications.
In this webinar, Dr. Rafael Carazo Salas describes multicolor, multiday high-content microscopy pipelines that his group has recently developed to visualize the dynamical cell fate changes of human Pluripotent Stem Cells (hPSCs). In particular, he reviews the integrated experimental and computational approaches that his group has established, including novel “live” reporters of cell fate and multi-reporter hPSC lines generated by CRISPR/Cas9 allowing multiplexed monitoring of cell proliferation and fate dynamics, and exemplify the biological discoveries they are enabling.
Key Topics Include:
- Visualizing how human Pluripotent Stem Cells (hPSCs) proliferate and undergo early differentiation in vitro, by high content microscopy
- Learning about experimental and computational pipelines that enable cell fate monitoring at the collective and single-cell level
- Learning about novel “live” reporters of hPSC cell fate
A novel method for building custom ampli seq panels using optimized pcr primers Thermo Fisher Scientific
AmpliSeq™ is a next generation sequencing library preparation method for targeted re-sequencing that utilizes highly multiplexed PCR to amplify regions of interest. A key to successful AmpliSeq libraries is the primer panel used for target amplification. Until now primers have been available as pre-assembled ready-to-use panels, or as custom made-to-order panels. We describe a new process for creating customized panels consisting of optimized and verified PCR primers. The primer sets are available as whole genes (i.e., all of the primers needed to create libraries that cover the entire coding regions of genes) and are selectable on the ampliseq.com website by either uploading gene lists or choosing genes from disease research areas.
We show NGS sequencing data from 10 disease research-oriented panels, including newborn screening research and inherited cancer research, assembled from individual pre-verified gene sets. Panel performance data include coverage uniformity, reproducibility, and sensitivity and positive predictive value of variant calling. To demonstrate flexibility of panel content and performance, the coverage uniformity of the 59 genes recommended by the American College of Medical Genetics and Genomics for reporting of incidental findings (ACMG59) was evaluated by themselves and with up to 135 additional genes and shown to be ≥ 97% in all contexts. We also demonstrate the robustness of this method using a variety of sample types (fresh, frozen, and dried blood, cheek swabs) with both manual and fully automated library preparation methods. For Research use only. Not for use in diagnostic procedures.
Conferència a càrrec d'Enriqueta Felip. Oncòloga de l'Hospital Vall d'Hebron de Barcelona. Líder en la investigació de càncer de pulmó al VHIO. Membre de la Junta Directiva de la Societat Espanyola d'Oncologia Mèdica i de l'European Society for Medical Oncology. En el marc de la Jornada "Els nous reptes de la Medicina de Precisió" organitzada el 12 de novembre per la Societat Catalana de Gestió Sanitària
Developing Custom Next-Generation Sequencing Panels using Pre-Optimized Assay...Thermo Fisher Scientific
Targeted next-generation sequencing panels enable interrogation of multiple genes across many samples to more deeply understand human genetic disease. However, finding all relevant genes, developing robust, high performing multiplex panels, and implementing scalable, reproducible and accurate analysis pipelines is challenging. We present a coordinated suite of tools to facilitate genetic disease research. First, we developed the Content Selection Engine which organizes human diseases hierarchically, and links all diseases to a set of associated genes; and the Gene Scoring Algorithm which ranks genes by clinical relevance. We developed optimized assays for the
most studied 1000 disease research genes, and we are in the process of developing optimized assays for a further 4000 genes.
An interactive web interface allows scientists to select any disease of interest, display all associated genes, select any genes, and add additional genes, for any number of diseases. Empirical coverage for each gene can be visualized in IGV. A custom Ampliseq gene panel can be built using the optimized assays from all the selected genes. Optimized gene panels can be developed narrowly targeted to specific diseases, or larger gene panels can be developed for broader phenotypes. Disease categories include early onset neonatal phenotypes such as metabolic disorders, Severe Combined Immunodeficiency (SCID), heme disorders; and late onset disorders such as cancer predisposition and cardiovascular disorders.
Sequencing and functional genomics Unit_Biomedical Research Center of Aragon_...Pilar Mozas
Documento que presenta la cartera de servicios y el equipamiento del Servicio Científico Técnico de Secuenciación y Genómica Funcional de la Universidad de Zaragoza y el Instituto Aragonés de Ciencias de la Salud.
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2QIAGEN
Advanced prostate cancer is highly heterogeneous but this inter-patient heterogeneity has until recently not been understood. We have through an international research effort dissected the molecular landscape of advanced castration resistant prostate, elucidating key molecular targets in this group of diseases. We have also shown that PARP inhibitors have antitumor activity against a significant proportion of these cancers, mainly in men whose cancers harbor DNA repair defects.
Validation of Identity and Ancestry
SNP Panels for the Ion PGM™
Christopher Phillips, Carla Santos, Maria de la Puente,
Manuel Fondevila, Ángel Carracedo, Maviky Lareu
Forensic Genetics Unit,
University of Santiago de Compostela
A high-throughput approach for multi-omic testing for prostate cancer researchThermo Fisher Scientific
The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).
mHealth Israel_Ryo Kosaka_AIST_National Institute of Advanced Industrial Scie...Levi Shapiro
Presentation by Ryo Kosaka, Senior Research Scientist, Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST). Includes an overview of priority strategies in Life Sciences and Biotech and description of the organization of the Life Sciences and Biotech department. Recent projects include a Portable System for High-Speed DNA Quantification, Application of a cell microarray chip for clinical diagnosis and single cell analysis, Safe and Secure Artificial Heart, New diagnosis for liver fibrosis utilizing glycans, AIST ventures from the department of Life Science & Biotech as well as International cooperation.
Course: Bioinformatics for Biomedical Research (2014).
Session: 2.1.2- Next Generation Sequencing. Technologies and Applications. Part II: NGS Applications I.
Statistics and Bioinformatisc Unit (UEB) & High Technology Unit (UAT) from Vall d'Hebron Research Institute (www.vhir.org), Barcelona.
In this presentation we showcase the latest advancements in myeloid genomic profiling: The Ion Torrent Oncomine Myeloid Assay GX.
Learn how this solution addresses key challenges in myeloid molecular testing and see recent data from the University of Pennsylvania.
Learn more at www.oncomine.com/myeloid
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that is genetically complex. Although great progress has been made in identifying fully penetrant mutations in genes that cause early-onset AD, these still represent a very small percentage of AD cases. Large-scale, genome-wide association studies (GWAS) have identified at least 20 additional genetic risk loci for the more common form: late-onset AD. However, the identified SNPs are typically not the actual risk variants, but are in linkage disequilibrium with the presumed causative variants [1].
To help identify causative genetic variants, we have combined highly accurate, long-read sequencing with hybrid-capture technology. In this collaborative webinar*, we present this method and show how combining IDT xGen® Lockdown® Probes with PacBio SMRT® Sequencing allows targeting and sequencing of candidate genes from genomic DNA and corresponding transcripts from cDNA. Using a panel of target capture probes for 35 AD candidate genes, we demonstrate the power of this approach by looking at data for two individuals with AD. Some additional benefits of this method include the ability to leverage long reads, phase heterozygous variants, and link corresponding transcript isoforms to their respective alleles.
Reference: 1. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med, 18(5):421–430.
* This presentation represents a collaboration between Pacific Biosciences and Integrated DNA Technologies. The individual opinions expressed may not reflect shared opinions of Pacific Biosciences and Integrated DNA Technologies.
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...QIAGEN
Traditional RNA sequencing (RNA-Seq) is a powerful tool for expression profiling, but is hindered by PCR amplification bias and inaccuracy at low expressing genes. QIAseq RNA is a flexible and precise tool developed for mitigating these complications, allowing digital gene expression analysis. This in-depth webinar will cover sample requirements, experimental design, NGS platform-specific challenges and workflow for gene enrichment, library prep and sequencing. The applications of QIASeq RNA Panels in cancer research, stem cell differentiation and elucidating the effects small molecules on signaling pathways will be highlighted.
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
In the rapidly evolving field of genomic analysis, staying current with the latest research, data sources, and test advancements is crucial. In this webinar, we review how VarSeq addresses the needs to stay on top of the latest with the release of VarSeq 2.6.0.
This release features an exome-optimized workflow for LOH and CNV calling as well as the introduction of VSPGx to produce pharmacogenomic reports for gene panels as well as exomes and genomes. With the recent release of gnomAD v4, we have had many requests for the integration of this large update to the most population frequency source. With VarSeq 2.6.0, the latest version of gnomAD has been integrated into VSClinical and the updated tracks spans beyond variants to cover CNVs and gene scores to update all your workflows to the latest data.
In this webcast, we will cover.
Improved VS-CNV performance and updated exome analysis workflows.
Pharmacogenomics in action: Utilizing VSPGx for exome and genome assessments.
gnomAD v4 in practice: Updated automated and manual variant interpretation workflows.
Join us for an insightful session on the latest VarSeq 2.6.0 features, bringing you the most up-to-date data and workflows for your genomic analysis.
High Through-Put DNA Methylation Analysis of Lung Cancer: Plasma cfDNA for Bi...Kate Barlow
• Technology pipeline for methylation biomarker
development
• High throughput DNA methylation-qPCR workflows
• Liquid biopsy – cfDNA methylation testing
Elevating Tactical DDD Patterns Through Object CalisthenicsDorra BARTAGUIZ
After immersing yourself in the blue book and its red counterpart, attending DDD-focused conferences, and applying tactical patterns, you're left with a crucial question: How do I ensure my design is effective? Tactical patterns within Domain-Driven Design (DDD) serve as guiding principles for creating clear and manageable domain models. However, achieving success with these patterns requires additional guidance. Interestingly, we've observed that a set of constraints initially designed for training purposes remarkably aligns with effective pattern implementation, offering a more ‘mechanical’ approach. Let's explore together how Object Calisthenics can elevate the design of your tactical DDD patterns, offering concrete help for those venturing into DDD for the first time!
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
Accelerate your Kubernetes clusters with Varnish CachingThijs Feryn
A presentation about the usage and availability of Varnish on Kubernetes. This talk explores the capabilities of Varnish caching and shows how to use the Varnish Helm chart to deploy it to Kubernetes.
This presentation was delivered at K8SUG Singapore. See https://feryn.eu/presentations/accelerate-your-kubernetes-clusters-with-varnish-caching-k8sug-singapore-28-2024 for more details.
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Ramesh Iyer
In today's fast-changing business world, Companies that adapt and embrace new ideas often need help to keep up with the competition. However, fostering a culture of innovation takes much work. It takes vision, leadership and willingness to take risks in the right proportion. Sachin Dev Duggal, co-founder of Builder.ai, has perfected the art of this balance, creating a company culture where creativity and growth are nurtured at each stage.
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
4. The OGT aCGH design process aCGH arrays All possible human genome probes Oligome TM database Further selection based on OGT probe rating and desired coverage and content Selection based on specificity, T m , GC, etc. Optimised array design for catalogue and custom products Design & hyb two different aCGH arrays Optimised aCGH design Selection of best performing probes based on experimental results
10. 407,787 human SNPs Select most informative SNPs (minor allele frequency of 0.4-0.6) 87,133 SNPs Elect candidate SNPs using OGT probe selection algorithms 19,489 SNPs Step 1: Selecting the SNPs What are the challenges? Microarray Design Analyse to determine functional probe designs
11. Step 1: Selecting the SNPs What are the challenges? Validation of UPD detection against clinical samples Validation on further set of known genotype samples 6,186 SNPs , each targeted by 2 optimised probes in triplicate, incorporated into 4x180k ISCA aCGH design of 137,100 copy number probes
ISCA developed with the ISCA steering committee. Optimised by OGT. Several groups have appreciated the cleaner calls and better coverage and have switched to the CytoSure platform. OGT is the exclusive distributor of the SciGene range of automated products for aCGH. Initially when labs move into using arrays they start using a manual approach. Our experience has shown that many labs quickly ramp up their sample numbers so automation becomes an important consideration. Having automation can also standardise results. Interestingly, OGT uses some of the Scigene products in its HT service facility. For example the Little Dipper for array washing and drying – also useful in FISH and GBanding. We have a Little Dipper on the booth this week if youd like to come and have a look.
Results Figure 1: Figure showing the SNP selection and probe design validation process used to identify probes capable of discriminating between SNP alleles
Results Figure 1: Figure showing the SNP selection and probe design validation process used to identify probes capable of discriminating between SNP alleles
